Core Insights - Evolus is experiencing signs of stabilization in the U.S. botulinum toxin market, while the recovery for dermal fillers is slower due to changing consumer sentiment [6][5] - The company has raised its long-term revenue targets for 2028, anticipating $450 million to $500 million, with adjusted EBITDA margins of 13% to 15% [15] Market Trends - The filler market is recovering slower than toxins, with negative sentiment around "overfilled" faces impacting hyaluronic acid (HA) fillers [2] - The company expects the market for toxins to return to mid-single-digit growth by 2027 and 2028, aligning with low-single-digit growth assumptions currently [3][5] Consumer Behavior - The 2024 downturn in the market is attributed to middle-class consumers reducing discretionary spending amid economic uncertainty, affecting all age groups and practice settings [4] - Consumers are stretching intervals between treatments to maximize the value of their spending [4] Product Launch and Technology - Evolus' new product, Evolysse, is gaining traction, currently available in about 3,000 U.S. clinics, and is expected to be a top HA launch despite broader category declines [8][12] - The technology behind Evolysse involves manufacturing HA gel at near-freezing temperatures to preserve its natural structure, leading to positive feedback from practitioners [8][9] Training and Adoption - The company has conducted hands-on training for over 12,000 injectors, with a second training session noted as a key factor in increasing product utilization [10] Strategic Initiatives - Evolus is bundling its products, Jeuveau and Evolysse, to enhance market share and compete more effectively against larger competitors [11][12] - The company has a consumer loyalty program with over 1.4 million participants, designed to encourage repeat visits to clinics [15] International Market Presence - Evolus has a direct presence in several European countries and Australia, with an estimated $2 billion opportunity in international markets for toxins and fillers [16] - The company expects international revenue to grow from 8% to about 15% of total revenue by 2028 [18]

Summary of Evolus Conference Call Company Overview - **Company**: Evolus - **Industry**: Aesthetic medicine, specifically focusing on toxins and fillers Key Points Market Dynamics - The toxin market is showing signs of recovery after a challenging period, with improvements noted in Q4 of the previous year and continuing into Q1 of the current year [4][8] - Historically, the toxin market has only experienced three significant downturns: the 2008-2009 recession, COVID-19 shutdowns, and the recent slowdown attributed to middle-class consumers reducing spending due to rising costs [4][5] - The current guidance suggests low single-digit growth for the toxin market, with expectations of mid-single-digit growth by 2027-2028 [9] Consumer Behavior - The slowdown in the toxin market was primarily driven by middle-class consumers stretching intervals between treatments, seeking to maximize their spending [5][7] - Consumer confidence is beginning to improve, leading to increased clinic activity and a slight uptick in the Consumer Confidence Index [7][8] Filler Market Insights - The filler market is recovering at a slower pace compared to the toxin market, impacted by negative perceptions around overfilled faces [14][17] - Clinics are shifting their messaging to promote hyaluronic acid (HA) as a natural ingredient rather than a filler, which is expected to improve consumer sentiment [16][17] Product Differentiation - Evolus's filler product, Evolysse, is performing well despite a challenging market, with clinics appreciating its efficiency and natural look [37][39] - The company has trained over 12,000 injectors to enhance confidence in using Evolysse, which is crucial for its adoption [39] Financial Guidance - For 2026, Evolus projects revenues between $327 million and $337 million, representing a 10%-13% year-over-year growth [80] - By 2028, the revenue is expected to reach between $450 million and $500 million, with adjusted EBITDA margins of 13%-15% [82] - International revenue is anticipated to grow from 8% in 2025 to 15% by 2028, driven by expanding market presence in Europe and new product launches [83][118] Strategic Initiatives - Evolus is focusing on bundling its products to enhance market share and customer loyalty, with a pilot program showing positive results [40][41] - The company is also investing in co-branded media to support clinics, maintaining an annual advertising spend of $9 million to $12 million [170] Customer Loyalty Program - Evolus has developed a consumer loyalty program with over 1.4 million active participants, which incentivizes repeat visits to clinics [164][200] - The program is designed to be frictionless and automated, enhancing customer engagement and clinic partnerships [208][210] Future Outlook - The upcoming launch of the Sculpt product is expected to be a significant revenue driver, potentially accounting for 40% of the filler line's revenue [102][106] - Evolus aims to continue expanding its product portfolio and market presence, with a focus on both U.S. and international markets [121][122] Additional Insights - The international market for toxins and fillers represents a $2 billion opportunity, with Evolus currently holding a low single-digit market share [134][140] - The company is actively monitoring market trends and consumer behavior to adapt its strategies accordingly [152][153]

Core Viewpoint - Evolus has achieved profitability, leading to a significant increase in its stock price by over 35% [1][4]. Group 1: Financial Performance - Evolus reported a revenue growth of 14% year over year, reaching $90.3 million in the fourth quarter [3]. - The company posted an operating profit of $4.2 million, a turnaround from a loss of $2.3 million in the same period last year [5][6]. - The gross margin for Evolus stands at 64.34% [5]. Group 2: Market Demand and Customer Satisfaction - The demand for Evolus' products, which improve the appearance of wrinkles and frown lines, is increasing, with reorder rates around 71% [3]. Group 3: Future Outlook - Evolus anticipates revenue growth of 10% to 13%, projecting revenues between $327 million and $337 million by 2026 [7]. - The company aims for sustainable profitability and meaningful free cash flow, which will provide financial flexibility for capital management and growth investments [7].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - Brand Engagement Network, Inc. (BNAI) is up 20% at $51.61 [3] - Latham Group, Inc. (SWIM) is up 20% at $7.79 [3] - Evolus, Inc. (EOLS) is up 14% at $4.74 [3] - Edesa Biotech, Inc. (EDSA) is up 11% at $4.86 [3] - 20/20 Biolabs, Inc. (AIDX) is up 11% at $3.28 [3] - DeFi Development Corp. (DFDV) is up 9% at $4.04 [3] - Accel Entertainment, Inc. (ACEL) is up 7% at $11.95 [3] - Solana Company (HSDT) is up 7% at $2.12 [3] - Nano-X Imaging Ltd. (NNOX) is up 6% at $2.76 [3] - Strive Asset Management, LLC (ASST) is up 5% at $8.81 [3] Premarket Losers - Battalion Oil Corporation (BATL) is down 28% at $19.67 [4] - TMD Energy Limited (TMDE) is down 24% at $3.03 [4] - Ascent Industries Co. (ACNT) is down 15% at $14.75 [4] - indie Semiconductor, Inc. (INDI) is down 14% at $2.71 [4] - WEBTOON Entertainment Inc. (WBTN) is down 13% at $9.98 [4] - STAAR Surgical Company (STAA) is down 10% at $17.00 [4] - Indonesia Energy Corporation Limited (INDO) is down 10% at $4.68 [4] - BiomX Inc. (PHGE) is down 7% at $4.52 [4] - Arbutus Biopharma Corporation (ABUS) is down 6% at $4.37 [4] - Global Interactive Technologies, Inc. (GITS) is down 6% at $2.43 [4]

分组1 - Evolus, Inc. reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.01 per share a year ago [1] - The company posted revenues of $90.3 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.98% and up from $78.95 million year-over-year [2] - Evolus shares have declined approximately 35.5% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Evolus is uncertain, with current consensus EPS estimates at -$0.11 for the coming quarter and -$0.04 for the current fiscal year, alongside revenues of $71.74 million and $330.94 million respectively [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 41% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Evolus was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% growth over Q4 2024, including $83.1 million from Jeuveau and $7.2 million from Evolysse [14][15] - For the full year 2025, global net revenue was $297.2 million, up 12% compared to 2024, marking the sixth consecutive year of double-digit growth [15][11] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at approximately 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] - Non-GAAP operating income for Q4 was $7.1 million, compared to $6.7 million in Q4 2024 [19] Business Line Data and Key Metrics Changes - Jeuveau captured over 14% U.S. market share, continuing to gain share even in a declining procedural environment [9] - Evolysse, introduced in 2025, has over 3,000 customers, expanding the company's presence within accounts [10] - International revenue nearly doubled year-over-year, now representing approximately 8% of total revenue, with strong growth in markets like the U.K. [15][10] Market Data and Key Metrics Changes - The U.S. injectable procedural volumes declined for only the third time in 25 years, yet Evolus achieved 12% revenue growth in 2025 [11] - The neurotoxin market declined mid to upper single digits in 2025, but Jeuveau gained units despite new competition [56] - The filler market is expected to see low single-digit growth, with signs of recovery anticipated [56][88] Company Strategy and Development Direction - Evolus aims to build a global performance beauty company centered on differentiated brands for cash pay consumers, with a focus on expanding its product portfolio [12][26] - The company plans to introduce Estyme in Europe in Q2 2026 and expects FDA approval of Evolysse Sculpt in Q4 2026 [12][26] - Evolus is committed to driving profitable growth, targeting revenue between $450 million to $500 million by 2028 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustained profitability beginning in 2026, with a low to mid-single-digit adjusted EBITDA margin expected [12][25] - The company noted that the aesthetic market is showing signs of recovery, particularly in the filler market, with expectations for gradual improvement [56][88] - Management highlighted the importance of customer loyalty programs and the positive feedback received from clinicians regarding product differentiation [32][56] Other Important Information - Evolus has entered into a revolving credit facility providing up to $30 million for working capital needs [21] - The company is not planning to raise equity capital and remains sensitive to dilution [22] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters? - Management noted that the customer base is diversifying, with over 3,000 purchasing accounts contributing to revenue growth [30] Question: Can Evolus turn around market growth impacted by macro trends? - Management believes that while macro factors affect the market, there are signs of improvement in the filler market [34] Question: Can you provide details on the rebate program structure? - The rebate program is designed to reward clinics for increased purchases, with eligibility based on quarterly purchase volumes [42][43] Question: How is the overall marketing strategy described for 2026? - The marketing strategy includes digital advertising and co-promotions with beauty brands, tailored to individual clinics [46][47] Question: What are the assumptions regarding competitive launches in guidance? - Management acknowledged the expected launch of new competitors in 2026 but remains confident in their product differentiation and market position [62][80]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% increase compared to Q4 2024, with Jeuveau revenue at $83.1 million and Evolysse at $7.2 million [14] - For the full year 2025, global net revenue reached $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth [15] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at about 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] - Cash at the end of Q4 was $53.8 million, up from $43.5 million at the end of Q3, driven by strong sales growth and disciplined expense management [19] Business Line Data and Key Metrics Changes - Jeuveau continues to capture over 14% of the U.S. market share, with sustained growth despite a declining procedural environment [9] - Evolysse, launched in 2025, has seen over 3,000 customers purchase the product, expanding the company's presence and share of injectable spend [10] - The company successfully piloted a new portfolio growth rebate program aimed at rewarding practices for increasing their business with Evolus [7] Market Data and Key Metrics Changes - International revenue nearly doubled year-over-year, now representing approximately 8% of total revenue, with strong growth in markets like the U.K. approaching double-digit market share [15][10] - The U.S. injectable procedural volumes declined for only the third time in 25 years, yet Evolus achieved a 12% revenue growth in 2025 [11] Company Strategy and Development Direction - Evolus aims to build a global performance beauty company focused on differentiated brands for cash-paying consumers, with plans to introduce Estyme in Europe and expect FDA approval for Evolysse Sculpt in Q4 2026 [12][26] - The company emphasizes education and training for clinicians, having provided hands-on training to over 14,000 clinicians in 2025 [8] Management's Comments on Operating Environment and Future Outlook - Management noted that the aesthetic market is showing signs of recovery, with expectations for low single-digit growth in the toxin market and gradual recovery in the filler market [55][89] - The company is optimistic about achieving profitability in 2026, with a target revenue between $450 million and $500 million by 2028 [12][25] Other Important Information - Evolus has entered into a revolving credit facility providing up to $30 million for working capital needs, supporting inventory build and preparation for product launches [21][22] - The company plans to transition its primary profitability metric to adjusted EBITDA starting in 2026 to improve comparability with industry peers [24] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters or is it starting to broaden? - Management indicated that Evolus is diversifying its customer base, with over 3,000 purchasing accounts and positive feedback on the portfolio rebate program [31] Question: Can Evolus turn around market growth impacted by macro trends? - Management believes that while macro factors affect the market, there are signs of improvement in the filler market, with clinicians adapting to new trends [35] Question: Can you provide details on the rebate program structure? - The rebate program is designed to reward clinics based on purchasing volume, with positive feedback received during the pilot phase [44] Question: How is the toxin market trending based on internal data? - Management noted that the neurotoxin market declined mid to upper single digits in 2025, but there are signs of recovery, especially in the latter half of the year [55] Question: What are the assumptions regarding competitive launches in guidance? - Management acknowledged upcoming competitive launches but emphasized the importance of maintaining focus on their differentiated clinical data and customer satisfaction [62]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% increase compared to Q4 2024, with Jeuveau revenue at $83.1 million and Evolysse at $7.2 million [13] - For the full year 2025, global net revenue reached $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth [14] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at about 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] Business Line Data and Key Metrics Changes - Jeuveau continues to capture over 14% of the U.S. market share, with sustained growth despite a declining procedural environment [8] - Evolysse, introduced in 2025, has seen over 3,000 customers purchase the product, expanding the company's presence and increasing overall share of injectable spend [9] - The Evolus Rewards program has grown to over 1.4 million treated patients, contributing to sustained share expansion [5] Market Data and Key Metrics Changes - International revenue nearly doubled year-over-year, now representing approximately 8% of global revenues, up from 5% in 2024 [14] - In key markets like the U.K., the company is approaching double-digit market share, reflecting strong positioning outside the U.S. [9] Company Strategy and Development Direction - The company aims to build a global performance beauty company centered on differentiated brands for cash pay consumers, with plans to introduce Estyme in Europe and expect FDA approval of Evolysse Sculpt [11][12] - The strategy includes a focus on education and training for clinicians, with over 14,000 clinicians trained in 2025 [6] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a unique year for the aesthetics market, with only the third decline in U.S. injectable procedural volumes in 25 years, yet the company achieved 12% revenue growth [10] - The outlook for 2026 includes expected revenue between $327 million and $337 million, representing 10% to 13% growth over 2025 results [22] Other Important Information - The company has entered into a revolving credit facility providing up to $30 million, which will be used for working capital needs [20] - The company does not plan to raise equity capital and remains sensitive to dilution [21] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters? - Management indicated that the customer base is diversifying, with over 3,000 purchasing accounts contributing to Jeuveau revenue, and plans to broaden the customer base through sampling and training programs [28][29] Question: Can you provide details on the rebate program structure? - The rebate program is designed as a growth rebate for accounts purchasing over $50,000 or $100,000 in a quarter, aimed at encouraging clinics to commit more business to Evolus [42][43] Question: How is the overall marketing strategy structured for 2026? - The marketing strategy includes digital advertising, billboards, and co-promotions with beauty brands, all customized for clinics [46][48] Question: What are the assumptions regarding competitive launches in guidance? - Management expects new entrants in 2026 to create pressure but believes that established brands will maintain their market share through quality and customer satisfaction [60][61] Question: How is the seasonality trend for Q1? - The toxin market is showing solid demand, while the filler market remains pressured but not experiencing the same declines as in 2025 [86]

Financial Performance - The company has incurred significant losses since inception, which may continue to adversely affect the market price of its common stock and ability to raise additional capital[14] - The terms of the Medytox Settlement Agreements will continue to reduce profitability[17] - The company may require additional financing for future operations, and failure to secure capital could force delays or reductions in operations[17] Competition and Market Challenges - The products Jeuveau and Evolysse™ face significant competition, and failure to compete effectively may hinder market share and expansion[14] - The company faces significant competition for its products, including Jeuveau and Evolysse™, which may hinder market share and expansion efforts[14] Consumer Spending and Economic Sensitivity - The company relies on consumer discretionary spending, which is sensitive to global economic conditions, potentially impacting sales[14] - The company's products rely on consumer discretionary spending, which is sensitive to global economic conditions, potentially impacting sales[14] Regulatory Approval and Compliance - Regulatory approval for the Evolysse™ product line in the United States is critical, and failure to maintain or obtain such approval could negatively affect sales[17] - The company is dependent on Symatese S.A.S. for regulatory approval of the Evolysse™ product line in the U.S., and failure to maintain or obtain approval could negatively affect sales[17] - The company must obtain additional regulatory approvals to expand product indications, which may be costly and not guaranteed[17] - The company is subject to extensive government regulation, which may result in delays or additional expenses in obtaining regulatory approvals[17] - The company is subject to extensive government regulation, which may result in delays or additional expenses related to regulatory compliance[17] Intellectual Property and Operational Risks - Third-party claims of intellectual property infringement may disrupt commercialization efforts and supply chains[17] - The company’s reliance on digital technology means that information system failures or cybersecurity incidents could significantly impact operations[17] - The company’s business and operations could suffer from information system failures or cybersecurity incidents[17] Licensing and Partnerships - The company relies on licensing agreements with Daewoong Pharmaceutical and Symatese, and loss of these rights could adversely affect business[17]

INVESTOR PRESENTATION MARCH 2026 2 This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and product candidates; the potential market ...